Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation. B, K., N, K., Ns, Y., Lm, C., B, G., A, A., Sb, E., G, O., A, O., E, K., Ta, C., M, G., & S, B. January, 2021. ISSN: 1573-2592 Publisher: J Clin Immunol![Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex 6 downloads Our findings suggest that improved disease management and immune dysregulatory profile can be achieved with ruxolitinib treatment before transplantation and this would be beneficial to reduce the risk of adverse outcome of HSCT.
@misc{b_stepwise_2021,
title = {Stepwise {Reversal} of {Immune} {Dysregulation} {Due} to {STAT1} {Gain}-of-{Function} {Mutation} {Following} {Ruxolitinib} {Bridge} {Therapy} and {Transplantation}},
url = {https://pubmed.ncbi.nlm.nih.gov/33475942/},
abstract = {Our findings suggest that improved disease management and immune dysregulatory profile can be achieved with ruxolitinib treatment before transplantation and this would be beneficial to reduce the risk of adverse outcome of HSCT.},
language = {en},
urldate = {2021-02-08},
journal = {Journal of clinical immunology},
author = {B, Kayaoglu and N, Kasap and Ns, Yilmaz and Lm, Charbonnier and B, Geckin and A, Akcay and Sb, Eltan and G, Ozturk and A, Ozen and E, Karakoc-Aydiner and Ta, Chatila and M, Gursel and S, Baris},
month = jan,
year = {2021},
pmid = {33475942},
doi = {10.1007/s10875-020-00943-y},
note = {ISSN: 1573-2592
Publisher: J Clin Immunol},
keywords = {CES, Clinical Exome, SOPHiA DDM},
}
Downloads: 6
{"_id":"KofDv9KsqsFFwcYhK","bibbaseid":"b-n-ns-lm-b-a-sb-g-etal-stepwisereversalofimmunedysregulationduetostat1gainoffunctionmutationfollowingruxolitinibbridgetherapyandtransplantation-2021","author_short":["B, K.","N, K.","Ns, Y.","Lm, C.","B, G.","A, A.","Sb, E.","G, O.","A, O.","E, K.","Ta, C.","M, G.","S, B."],"bibdata":{"bibtype":"misc","type":"misc","title":"Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/33475942/","abstract":"Our findings suggest that improved disease management and immune dysregulatory profile can be achieved with ruxolitinib treatment before transplantation and this would be beneficial to reduce the risk of adverse outcome of HSCT.","language":"en","urldate":"2021-02-08","journal":"Journal of clinical immunology","author":[{"propositions":[],"lastnames":["B"],"firstnames":["Kayaoglu"],"suffixes":[]},{"propositions":[],"lastnames":["N"],"firstnames":["Kasap"],"suffixes":[]},{"propositions":[],"lastnames":["Ns"],"firstnames":["Yilmaz"],"suffixes":[]},{"propositions":[],"lastnames":["Lm"],"firstnames":["Charbonnier"],"suffixes":[]},{"propositions":[],"lastnames":["B"],"firstnames":["Geckin"],"suffixes":[]},{"propositions":[],"lastnames":["A"],"firstnames":["Akcay"],"suffixes":[]},{"propositions":[],"lastnames":["Sb"],"firstnames":["Eltan"],"suffixes":[]},{"propositions":[],"lastnames":["G"],"firstnames":["Ozturk"],"suffixes":[]},{"propositions":[],"lastnames":["A"],"firstnames":["Ozen"],"suffixes":[]},{"propositions":[],"lastnames":["E"],"firstnames":["Karakoc-Aydiner"],"suffixes":[]},{"propositions":[],"lastnames":["Ta"],"firstnames":["Chatila"],"suffixes":[]},{"propositions":[],"lastnames":["M"],"firstnames":["Gursel"],"suffixes":[]},{"propositions":[],"lastnames":["S"],"firstnames":["Baris"],"suffixes":[]}],"month":"January","year":"2021","pmid":"33475942","doi":"10.1007/s10875-020-00943-y","note":"ISSN: 1573-2592 Publisher: J Clin Immunol","keywords":"CES, Clinical Exome, SOPHiA DDM","bibtex":"@misc{b_stepwise_2021,\n\ttitle = {Stepwise {Reversal} of {Immune} {Dysregulation} {Due} to {STAT1} {Gain}-of-{Function} {Mutation} {Following} {Ruxolitinib} {Bridge} {Therapy} and {Transplantation}},\n\turl = {https://pubmed.ncbi.nlm.nih.gov/33475942/},\n\tabstract = {Our findings suggest that improved disease management and immune dysregulatory profile can be achieved with ruxolitinib treatment before transplantation and this would be beneficial to reduce the risk of adverse outcome of HSCT.},\n\tlanguage = {en},\n\turldate = {2021-02-08},\n\tjournal = {Journal of clinical immunology},\n\tauthor = {B, Kayaoglu and N, Kasap and Ns, Yilmaz and Lm, Charbonnier and B, Geckin and A, Akcay and Sb, Eltan and G, Ozturk and A, Ozen and E, Karakoc-Aydiner and Ta, Chatila and M, Gursel and S, Baris},\n\tmonth = jan,\n\tyear = {2021},\n\tpmid = {33475942},\n\tdoi = {10.1007/s10875-020-00943-y},\n\tnote = {ISSN: 1573-2592\nPublisher: J Clin Immunol},\n\tkeywords = {CES, Clinical Exome, SOPHiA DDM},\n}\n\n","author_short":["B, K.","N, K.","Ns, Y.","Lm, C.","B, G.","A, A.","Sb, E.","G, O.","A, O.","E, K.","Ta, C.","M, G.","S, B."],"key":"b_stepwise_2021","id":"b_stepwise_2021","bibbaseid":"b-n-ns-lm-b-a-sb-g-etal-stepwisereversalofimmunedysregulationduetostat1gainoffunctionmutationfollowingruxolitinibbridgetherapyandtransplantation-2021","role":"author","urls":{"Paper":"https://pubmed.ncbi.nlm.nih.gov/33475942/"},"keyword":["CES","Clinical Exome","SOPHiA DDM"],"metadata":{"authorlinks":{}},"downloads":6},"bibtype":"misc","biburl":"https://bibbase.org/zotero/SOPHiAGENETICS","dataSources":["Pcpsxmwz8uxXtL843","vPYMrJTaJTbhFPPb4"],"keywords":["ces","clinical exome","sophia ddm"],"search_terms":["stepwise","reversal","immune","dysregulation","due","stat1","gain","function","mutation","following","ruxolitinib","bridge","therapy","transplantation","b","n","ns","lm","b","a","sb","g","a","e","ta","m","s"],"title":"Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation","year":2021,"downloads":6}